# Single Dose of Psilocybin Improves Depressive Symptoms in Phase 2 Study

![rw-book-cover](https://readwise-assets.s3.amazonaws.com/static/images/article2.74d541386bbf.png)

## Metadata
- Author: [[readwise.io]]
- Full Title: Single Dose of Psilocybin Improves Depressive Symptoms in Phase 2 Study
- Category: #articles
- URL: https://readwise.io/reader/document_raw_content/112410705

## Highlights
- single 25-mg dose of psilocybin ad- ministered with psychological support led to significant and sustained improvement in depressive symptoms compared with pla- cebo in a Phase 2 study of patients with major depressive disorder ([View Highlight](https://read.readwise.io/read/01hfvr97g0gc4hg6tsft39m5hv))
- t no serious treatment-emergent adverse events were reported ([View Highlight](https://read.readwise.io/read/01hfvr9kxh8s3y9xffkd97557m))
- maintained across the 6-week fol- low-up period, without attenuation of the effect, and with higher point prevalence rates of MADRS-defined response and re- mission than has been observed in recent psilocybin studies of [treatment-resistant depression],” ([View Highlight](https://read.readwise.io/read/01hfvs16fh220gk16984qmavq1))
- it
  is possible that
  psilocybin and other psychedelics produce
  adverse events
  that conventional rating
  scales do not capture. ([View Highlight](https://read.readwise.io/read/01hfvrz8p1jqrnjkf517bysary))
- Among those excluded were individuals with a personal or first-degree family history of psychosis or mania, those with a moderate or severe substance use disorder, and those who had used a psychedelic drug in the past 5 years or more than 10 times over their lifetime. ([View Highlight](https://read.readwise.io/read/01hfvrfqkv9gng68xrhr9fagd4))
- A higher number of participants receiving psilocybin experienced sustained response. The sustained remission rate appeared greater in the psilocybin group, but the difference was not significant. ([View Highlight](https://read.readwise.io/read/01hfvrvppp19nyzvc1bbbtvgha))
- the study population lacked racial diversity, which has been a shortcoming of most studies of psychedelics. The in- vestigators suggested that large-scale and longer-term studies are needed in order to evaluate the potential of psilocybin treat- ment for chronic depression. ([View Highlight](https://read.readwise.io/read/01hfvrzyfywtnm5rz0vpy5jrt3))
- Only four of 50 participants in the psilocybin group experienced a severe adverse event, and no participants withdrew from the study due to an adverse event. Headache and nausea were the most commonly reported adverse events. No participants exhibited suicidal behavior. ([View Highlight](https://read.readwise.io/read/01hfvrxjbrnc13vayrnmgm67bn))
- “Improvements in depression were ap- parent within 8 days of psilocybin dosing, ([View Highlight](https://read.readwise.io/read/01hfvs0gzdd63gqyea9b261ecs))
## New highlights added December 5, 2023 at 9:14 PM
- Montgomery-Asberg Depression Rating Scale ([View Highlight](https://read.readwise.io/read/01hg4rb7zqe921s7fjf1gkamjd))
- was larger than the difference that is used to denote substan- tial clinical improvement in patients with treatment-resistant depression ([View Highlight](https://read.readwise.io/read/01hg4rn441pbjzxpztjnm0v0hn))
